TechneLite Technetium Tc99m Generator

Mo-99 and Tc-99m: Critical to Nuclear Medicine

Molybdenum-99 (Mo-99) is the parent isotope of technetium-99m (Tc-99m), which is the radioisotope most widely utilized for nuclear medicine diagnostic imaging tests.

What is TechneLite®?

TechneLite® is a technetium-99m (Tc-99m) generator that provides the essential medical isotope used by hospitals and radiopharmacies to radiolabel Cardiolite® (Kit for the Preparation of Technetium Tc-99m Sestamibi for Injection) and other radiopharmaceuticals requiring Tc-99m used in nuclear medicine imaging procedures.

Learn More

Lantheus Medical Imaging - committed to meeting the needs of the nuclear medicine community


Commitment to Reliable Access

Lantheus is committed to ensuring that the medical imaging community has reliable and secure access to TechneLite® (Technetium Tc-99m Generator) to meet the healthcare needs of patients. In order to ensure the consistency and reliability that are the hallmarks of the TechneLite® brand, the generators are calibrated on-site on the same day of manufacturing every Monday, Tuesday, Friday and Sunday.

Diversified Supply Chain

As a result of aging and increasingly less reliable nuclear reactors that supply Mo-99, Lantheus has aggressively undertaken several key initiatives to implement a diversified and balanced supply chain of Mo-99 for its TechneLite® generators. The company has secured numerous partnerships and agreements with suppliers and partners worldwide to maximize access to this important medical isotope.


Lantheus production of technetium-99: From the reactor to the patient

First Company to Use LEU-Derived Mo-99

There are a number of worldwide suppliers of Mo-99. All of the supply is imported into the United States from nuclear reactors that primarily use highly enriched uranium (HEU) targets, which pose a global security threat. In December 2010, Lantheus announced the distribution of TechneLite® generators using Mo-99 produced with low-enriched uranium (LEU) targets, making Lantheus the first company to use Mo-99 sourced from LEU in the United States.1,2


Lantheus Medical Imaging, Inc.Lantheus Medical Imaging is a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents. Lantheus provides a broad portfolio of products, which are primarily used for the diagnosis of cardiovascular diseases.

Clinicians use our imaging agents and products across a range of imaging modalities, including nuclear imaging, echocardiography and magnetic resonance imaging (MRI).

Our expertise in discovering, developing and commercializing innovative medical imaging agents provides a strong platform to bring forward breakthrough tools for the diagnosis and management of disease.

Lantheus is headquartered in North Billerica, Massachusetts with offices in Puerto Rico, Canada and Australia.

For more information, visit

References: 1. National Nuclear Security Administration - U.S. Department of Energy, 2010. First LEU-Produced Molybdenum-99 Approved for Patient Use Arrives in U.S. [press release], 6 December 2010, Available at: <> [Accessed 30 July 2012] 2. Lantheus Medical Imaging, 2010. Lantheus Medical Imaging Announces First Commercial Production of TechneLite® Generators from Low-Enriched Uranium-Produced Molybdenum-99. [press release], 6 December 2012, Available at: <> [Accessed 30 July 2012]


The TechneLite® generator is a source of sodium pertechnetate Tc 99m for use in the preparation of FDA-approved diagnostic radiopharmaceuticals, as described in the labeling of these diagnostic radiopharmaceutical kits. 

Sodium Pertechnetate Tc 99m Injection is used IN ADULTS as an agent for:
Thyroid Imaging
Salivary Gland Imaging
Urinary Bladder Imaging (direct isotopic cystography) for the detection of vesico-ureteral reflux.
Nasolacrimal Drainage System Imaging

Sodium Pertechnetate Tc 99m Injection is used IN CHILDREN as an agent for:
Thyroid Imaging
Urinary Bladder Imaging (direct isotopic cystography) for the detection of vesico-ureteral reflux.


None Known.

Important Safety Information:

Allergic reactions including anaphylaxis have been reported infrequently following the administration of Sodium Pertechnetate Tc 99m Injection.


Radiation risks associated with the use of Sodium Pertechnetate Tc 99m Injection are greater in children than in adults and, in general, the younger the child, the greater the risk owing to greater absorbed radiation doses and longer life expectancy.
These greater risks should be taken firmly into account in all benefit-risk assessments involving children.  Long-term cumulative radiation exposure may be associated with an increased risk of cancer.


Since the eluate does not contain an antimicrobial agent, it should not be used after 12 hours from the time of TechneLite®, Technetium Tc 99m Generator, elution. After the termination of the nasolacrimal imaging procedure, blowing the nose and washing the eyes with sterile distilled water or an isotonic sodium chloride solution will further minimize the radiation dose. As in the use of any radioactive material, care should be taken to minimize radiation exposure to patients and occupational workers. Radiopharmaceuticals should be used only by physicians who are qualified by training and experience and who are licensed in the safe handling of radionuclides.

Please see full Prescribing Information


To place an order call 1-800-299-3431 or visit